Generic Name and Formulations:
Diatrizoate meglumine 527mg, iodipamide meglumine 268mg; per mL; soln for intrauterine instillation; contains sodium 0.91mg/mL, organically bound iodine 380mg/mL.
Indications for SINOGRAFIN:
See literature for information on administration and radiography. Empty bladder before exam. 3–4mL administered in fractional doses of approx. 1mL are usually adequate to visualize the uterus; an additional 3–4mL will demonstrate the tubes. Total doses of 1.5–10mL have been used.
Pregnancy. During menstrual period. External genitalia or genital tract infection. Within 30 days of curettage or conization or within 6 months following termination of pregnancy.
Should be performed by personnel trained in diagnostic procedures that involve radiopaque diagnostic agents. Carcinoma of the uterus and/or uterine/tubes; possible dispersion of carcinogenic cells during procedure. History of asthma/allergy. Nursing mothers.
May interfere with thyroid tests.
Radiopaque contrast medium.
Dizziness, syncope, hypotension, chills, fever, nausea, vomiting, abdominal pain and tenderness, hypersensitivity reactions; rare: bradycardia, hypotension, cardiac arrest, death.
Single-dose vial (10mL)—10
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use